Laura J. Esserman

The paper identifies hormone signaling and immune programs as factors determining endocrine responsiveness in breast tissue with background parenchymal enhancement.

The paper systematically identifies and characterizes cancer-emergent oncRNAs across 32 tumor types, showing they act as blood-accessible molecular barcodes for cancer identity and prognosis.

The paper develops predictive models using patient-derived breast cancer organoids to identify drug responses and guide new therapies for resistant disease.

This study shows that fine needle aspiration biopsy (FNAB) effectively harvests cells for patient-derived organoids modeling breast ductal carcinoma in situ, with faster growth times compared to core needle biopsy.

This study compares gut and oral microbiota in women with breast cancer, ductal carcinoma in situ, and healthy controls, finding significant gut microbiota differences but not oral ones.

The paper creates a breast pre-cancer atlas by analyzing multiple micro-dissected regions from DCIS cases, revealing molecular and micro-environmental diversity and immune states associated with progression risk.

This paper develops a method to improve mutational profiling of pre-malignant lesions using degraded FFPE DNA, achieving better coverage and variant calling accuracy.

The paper introduces a clinical benefit index (CBI) to quantify and integrate drug efficacy and toxicity using patient-reported outcomes for adaptive randomization and regulatory evaluation.